Boehringer’s Engelbert Tjeenk Willink leaves firm
pharmafile | September 28, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Boehringer Ingelheim, Engelbert Tjeenk Willink
Boehringer Board member Engelbert Tjeenk Willink, responsible for Marketing and Sales of Prescription Medicines, has decided to leave at the end of this year.
The firm’s shareholders have appointed Allan Hillgrove as new member of the Board of managing directors. Hillgrove, 52, will assume responsibility for the Board Division Marketing and Sales Prescription Medicines from the new year.
Hillgrove who is an Australian national has been part of the Group since 1982 and worked as head of Established Markets since 2010.
Christian Boehringer, chairman of the shareholders committee and Prof Andreas Barner, chairman of the Board of managing directors said: “On behalf of the shareholders and the Board of managing directors, we would like to thank Mr Engelbert Tjeenk Willink for his many years of dedicated and successful work for the company. We are sorry to see him go and wish him all the best in his future professional and personal life.
“We welcome Mr Allan Hillgrove to the Board of managing directors as an experienced colleague who has got to know the organisation very well in over 30 years. In his various roles he has helped to set the course for sustained growth in recent years.”
Tjeenk Willink was head of Marketing for Prescription Medicines at Boehringer Ingelheim GmbH from 2001 to 2005. Before that he acted as head of Marketing and Sales in Canada, and from 2005 to 2008 he worked as country manager of Boehringer Ingelheim Mexico.
Related Content
Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis
Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a …
Boehringer Ingelheim acquires Nerio Therapeutics, strengthening immune-oncology profile
Biopharmaceutical company Boehringer Ingelheim has announced the acquisition of drug discovery and development company Nerio …
Brainomix and Boehringer Ingelheim enter strategic partnership
Brainomix has announced that it has entered into a strategic partnership with Boehringer Ingelheim for …
